Moderna Stock Prediction and Forecast [MRNA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 26 Aug 2025, 03:20 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Moderna Stock Prediction and Forecast [MRNA]](https://i.ytimg.com/vi/yGej894p0lo/hqdefault.jpg)
AI-generated source summary
The video presents a bearish technical analysis of MRNA, stating that since August 22nd, 2025, MRNA is considered a sell candidate, with a score of -3.06. It shows a 6.53% loss over two days. 3-month trend indicates a 4.22% change with a possible range of 4.22% to 44.72%. The 12-month analysis suggests a -52.07% change in price over the next year, and possible drop $5.69 to $18.76. The last trading day showed a 6.53% decline. It is mentioned that approval and sentiment may lift sentiment while weak guidance and policy create volatility. The analysts' consensus is SELL. It is suggested monitoring a potential BUY signal on 3-Month MACD. A long-term average suggests to sell the stock if it rises above $27.09 and $29.84, given the increased volume when prices decreased. Also, that there isn’t a strong level of support. All this points out to MRNA stock decreasing over the course of the next twelve months. A Stop-Loss wasn't able to be determined due to the bearish evaluation.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
